FilingReader Intelligence
Huadong Medicine stroke drug application accepted by regulator
July 30, 2025 at 05:36 PM UTC•By FilingReader AI
Huadong Medicine's subsidiary Hangzhou Sino-America Huadong Pharmaceutical received acceptance from China's drug regulator for TTYP01, an oral tablet for acute ischemic stroke patients.
The company invested approximately 100.81m yuan in the project, including an initial 100m yuan payment for the project introduction.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000963•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Huadong Medicine publishes news
Free account required • Unsubscribe anytime